More recently, the European Society for Medical Oncology (ESMO) recommends the adoption of NGS technology in patient with advanced non-squamous NSCLC to analyze not only DNA-based biomarkers but also RNA-based gene rearrangements and other alterations, such as MET exon 14 skipping mutations. This evidence concerns the gene MET and non-small cell lung carcinoma.